SCHEMBL30730616

SCHEMBL30730616

Cc1nonc1CC(=O)N1CC2CC1CC2c1nc(C2CCCCC2)no1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.37
PKM P14618 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CPT1A P50416 5/20 0.34
CPT2 P23786 4/20 0.34
GFER P55789 1/20 0.34
DPP4 P27487 3/20 0.33
PREP P48147 3/20 0.33
DPP8 Q6V1X1 3/20 0.33
DPP9 Q86TI2 3/20 0.33
DPP7 Q9UHL4 3/20 0.33
TSHR P16473 2/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676800 0.89 GRM5 (0.33) PKMALDH1A1GFERDPP4PREP
SCHEMBL30730680 0.88 PKM (0.33) PKMALDH1A1CPT1ACPT2GFER
SCHEMBL30730444 0.85 HSD11B1 (0.37) HSD11B1CPT1ACPT2DPP4PREP
SCHEMBL30730635 0.78 GRM5 (0.43) HSD11B1ALDH1A1TSHRHTTGRM5
SCHEMBL30730506 0.77 HSD11B1 (0.46) HSD11B1PKMALDH1A1CPT1ACPT2
SCHEMBL30730608 0.76 HSD11B1 (0.44) HSD11B1PKMALDH1A1CPT1ACPT2
SCHEMBL32677029 0.76 GRM5 (0.41) PKMALDH1A1CPT1AGFERGRM5
SCHEMBL30730547 0.76 PKM (0.38) PKMCPT1ACPT2GRM5
SCHEMBL32676615 0.75 GRM5 (0.33) HSD11B1CPT1ACPT2DPP4PREP
SCHEMBL30730687 0.74 PKM (0.43) HSD11B1PKMALDH1A1CPT1ACPT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 HSD11B1 235/4885PKM 2873/4885ALDH1A1 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.